Comment on "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update"
- PMID: 33738757
- PMCID: PMC8052227
- DOI: 10.1007/s40265-021-01494-1
Comment on "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update"
Conflict of interest statement
The authors declare that they have no conflict of interest related to this letter, except that they themselves had carried out two reviews about the highly debated topic of pregabalin´s and gabapentin´s harms and addiction [11, 22]. Furthermore, Norbert Scherbaum received honoraria for several activities (advisory boards, lectures, manuscripts) from AbbVie, Camurus, Hexal, Janssen-Cilag, MSD, Medice, Mundipharma, Reckitt-Benckiser/Indivior, and Sanofi-Aventis. During the last 3 years he participated in clinical trials financed by the pharmaceutical industry.
Figures
Comment in
-
Authors' Reply to Bonnet et al. "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update".Drugs. 2021 Apr;81(5):615-617. doi: 10.1007/s40265-021-01495-0. Epub 2021 Mar 18. Drugs. 2021. PMID: 33738758 No abstract available.
Comment on
-
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update.Drugs. 2021 Jan;81(1):125-156. doi: 10.1007/s40265-020-01432-7. Drugs. 2021. PMID: 33215352
References
-
- Oxford Centre for evidence-based medicine: levels of evidence. 2009. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for.... Accessed 1 Jan 2021.
-
- Hayes AF. Mediation, moderation, and conditional process analysis. 2. New York: Guilford Press; 2018.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
